首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 核酸药物

市场调查报告书

商品编码

1272658

多□治疗市场：现状分析与预测（2022-2030）

Peptide Therapeutics Market: Current Analysis and Forecast (2022-2030)

出版日期: 2023年04月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 156 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

由于新药开发的製药投资增加，预计□治疗市场在预测期内将以 9% 的复合年增长率增长。例如，2021 年 9 月，Nimble Therapeutics 与 Incyte 合作发现了新型□疗法。此外，2020 年 7 月，IRBM 启动了与默克公司的研究合作，以开发先进的□疗法。预计此类投资将推动未来几年的市场增长

根据药物类型，市场分为品牌药和仿製药。 2021年品牌产品将占据较大市场份额，主要是由于药企加大研发投入、产品上市以及高处方率。

按给药途径，药物分为母体剂、粘膜剂、口服剂和透皮剂。父类别将在 2021 年主导市场。高采用率、快速给药和易于使用等几个因素是全球市场采用率不断提高的主要原因。目前，大多数□疗法是通过亲本途径递送的，这也将在未来几年推动市场增长。

按照应用，市场分为癌症、新陈代谢、心血管疾病、呼吸系统、血液疾病、抗感染、皮肤科、中枢神经系统等。由于□疗法的高特异性和靶向性，预计肿瘤学领域在预测期内将以高复合年增长率增长。癌症患病率激增、产品快速上市以及研发活动增加等其他因素也推动了这一领域的增长。例如，2021 年 6 月，Nimble Therapeutics 宣布与 RayzeBio 合作，发现和开髮用于治疗癌症的新型□类放射性药物。

按分销渠道，市场分为医院药店、零售药店和在线药店。预计在线药店在预测期内将实现高复合年增长率。在线药店的需求预计将受到互联网使用量增加、远程医疗采用增加、技术采用增加、便利性和时间效率等因素的影响。还有知名的电子药房玩家，他们提供的节省也有望在不久的将来支持细分市场的需求。

为了更好地了解□治疗行业的市场采用情况，将市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、意大利、欧洲其他地区） )、亚太地区（中国、日本、印度、亚太地区其他地区），以及世界其他地区，基于他们的全球规模。根据 Globocan 2020 报告，预计 2020 年美国将有 2,281,658 例新癌症诊断和近 612,390 例死亡。除此之外，主要参与者的存在、製药公司增加投资以及政府有利的监管政策也推动了该地区的市场增长。例如，2022 年 7 月，Peptilogics 获得了美国 FDA 对 PLG0206 的快速通道指定，用于治疗假体周围关节感染（ PJI ）。

内容

第一章市场介绍

市场定义
主要目的
利益相关者
限制

第 2 章研究方法或假设

研究过程
调查方法
受访者简介

第三章市场总结

第 4 章执行摘要

第 5 章 COVID-19 对□治疗市场的影响

第六章多□药物市场收入，2020-2028F

第 7 章市场洞察：按药物类型分类

品牌
通用的

第 8 章市场洞察：按管理途径

静脉注射
经粘膜
口语
透皮

第 9 章市场洞察：按应用

癌症
新陈代谢
心血管疾病
呼吸系统
血液病
传染病的对策
皮肤科
中枢神经系统
其他

第 10 章市场洞察：按分销渠道

医院药房
零售药房
在线药店

第 11 章市场洞察：按地区

北美
- 美国
- 加拿大
- 其他北美地区
欧洲
- 德国
- 英国
- 法国
- 意大利
- 西班牙
- 其他欧洲地区
亚太地区
- 中国
- 日本
- 印度
- 其他亚太地区
世界其他地区

第十二章□治疗市场动态

市场驱动因素
市场挑战

第十三章□治疗市场机会

第14章多□药物市场趋势

第15章需求侧与供给侧分析

需求方分析
供应方分析

第16章价值链分析

第 17 章衝突场景

竞争格局
- 波特五力分析

第 18 章公司简介

AbbVie Inc.
Pfizer Inc.
Lilly
Amgen Inc.
Bristol-Myers Squibb Company
Takeda Pharmaceutical Company Limited
Sanofi
F. Hoffmann-La Roche Ltd
GSK plc
Novartis AG

第十九章免责声明

简介目录

Product Code: UMAU211767

Peptides are a combination of two or more amino acid monomers linked by amino acids. They act as efficient signaling molecules which bind to specific cell surface receptors, including ion channels and G protein-coupled receptors, and trigger intracellular effects. Researchers are actively utilizing peptides for the development of novel formulations indicated for the management of a wide range of acute and chronic diseases. . According to the American Cancer Society, "Cancer and Figures 2022", there was an estimated 1.9 million new cancer cases diagnosed in 2022. Moreover, as per the same source in 2020, the most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the U.S. Thus, the increasing cases of cancer require early treatment which is expected to increase the demand for peptide therapeutics over the forecast period.

The Peptide Therapeutics Market is expected to grow at a strong CAGR of 9% during the forecast period owing to the rising pharmaceutical investment for the development of novel drugs. For instance, in September 2021, Nimble Therapeutics collaborated with Incyte to discover novel peptide therapeutics. Further in July 2020, IRBM entered into a collaboration with Merck for the development of advanced peptide therapeutics. Such investments are expected to drive the market growth in the coming years

Based on drug type, the market is bifurcated into branded and generic. The branded category held a significant share of the market in 2021 mainly due to the rising research and development investment by pharmaceutical companies, product launches, and high prescription rates.

By route of administration, the market is segmented into parental, mucosal, oral, and transdermal. The parental category held a dominant share of the market in 2021. Several factors, such as high adoption rate, faster delivery of drugs, and ease of application are the major reasons for increasing their adoption in the global market. Currently, the majority of peptide therapeutics are delivered by parental route, which is also driving the market growth during the coming years.

On the basis of application, the market is segmented into cancer, metabolic, cardiovascular disorders, respiratory, hematological disorders, anti-infection, dermatology, CNS, and others. The cancer category is anticipated to grow with high CAGR during the forecast period owing to the high specificity and targetability of peptide therapeutics. Other factors, such as a surge in the prevalence of cancer, rapid product launches, and increasing research and development activities are also driving the segment growth. For instance, in June 2021, Nimble Therapeutics announced a collaboration with RayzeBio to discover and develop novel peptide-based radiopharmaceuticals for the treatment of cancer.

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Online pharmacies are expected to register a high CAGR during the forecast period. The demand for the online pharmacy segment is projected to be influenced by factors such as the rise in internet usage, rising telemedicine adoption, rising technology adoption, and convenience and time efficiency. Also, the availability of well-known e-pharmacy players and the savings they provide are expected to support segment demand in the near future.

For a better understanding of the market adoption of the peptide therapeutics industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held a dominant share in the market in 2021 owing to increased adoption of targeted therapy and rise in the incidence of cancer in U.S. According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the U..S in 2020, with nearly 612,390 deaths. Apart from this, the presence of major key players, rising investments by pharmaceutical companies, and favorable government regulatory policies are also propelling the regional market growth. For instance, in July 2022, Peptilogics received U.S. FDA fast-track designation for PLG0206, for the treatment of periprosthetic joint infection (PJI).

Some of the major players operating in the market include: AbbVie Inc.; F. Hoffmann-La Roche Ltd; Amgen Inc.; Pfizer Inc.; Bristol-Myers Squibb Company; Lilly; Sanofi; GSK plc; Novartis AG; and Takeda Pharmaceutical Company Limited.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Peptide Therapeutics Market
2.2. Research Methodology of the Peptide Therapeutics Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE PEPTIDE THERAPEUTICS MARKET

6 PEPTIDE THERAPEUTICS MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY DRUG TYPE

7.1. Branded
7.2. Generic

8 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

8.1. Parental
8.2. Mucosal
8.3. Oral
8.4. Transdermal

9 MARKET INSIGHTS BY APPLICATION

9.1. Cancer
9.2. Metabolic
9.3. Cardiovascular Disorder
9.4. Respiratory
9.5. Haematological Disorders
9.6. Anti-infection
9.7. Dermatology
9.8. CNS
9.9. Others

10 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

10.1. Hospital Pharmacies
10.2. Retail Pharmacies
10.3. Online Pharmacies

11 MARKET INSIGHTS BY REGION

11.1. North America
- 11.1.1. U.S.
- 11.1.2. Canada
- 11.1.3. Rest of North America
11.2. Europe
- 11.2.1. Germany
- 11.2.2. U.K.
- 11.2.3. France
- 11.2.4. Italy
- 11.2.5. Spain
- 11.2.6. Rest of Europe
11.3. Asia-Pacific
- 11.3.1. China
- 11.3.2. Japan
- 11.3.3. India
- 11.3.4. Rest of Asia-Pacific
11.4. Rest of World